Oncotarget

Corrections:

Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST

PDF  |  How to cite

Oncotarget. 2021; 12:2435-2436. https://doi.org/10.18632/oncotarget.28137

Metrics: PDF 31 views  |   ?  

Hsiang-Chih Lu1,*, Vanessa Eulo2,*, Anthony J. Apicelli3,4, Melike Pekmezci5, Yu Tao6, Jingqin Luo6, Angela C. Hirbe7,4 and Sonika Dahiya1,4

1Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
2Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
3Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
4Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA
5Department of Pathology, University of California San Francisco School of Medicine, San Francisco, CA, USA
6Siteman Cancer Center Biostatistics Shared Resource, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
7Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA
*Co-first authors

Published: November 23, 2021

Copyright: © 2021 Lu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The Supplementary Table 2 has been updated to show the appropriate WUSTL numbers in the first column. The corrected Table 2, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:23018–23028. DOI: https://doi.org/10.18632/oncotarget.25195


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28137